Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Document › Details

Antabio S.A.S.. (7/12/18). "Press Release: Antabio Completes € 12.5m Series A. New Investors Omnes, BNP Paribas Développement and Sham Innovation Santé Invest an Additional €5.2m". Labège.

Organisations Organisation Antabio S.A.S.
  Organisation 2 Omnes Capital S.A.S.
Products Product antibiotic
  Product 2 venture capital
Index terms Index term Antabio–SEVERAL: investment, 201807 2nd closing financing round Series A €5.2m bringing total Series A to €12.5m
  Index term 2 Antabio–CARB-X: grant, 201707– grant up to $8.9m to support developm of PEI program for pseudomonas infections in CF
Persons Person Lemonnier, Marc (Antabio 201302 CEO)
  Person 2 Poulard, Claire (Omnes Capital 201807 Associate)
     


New investors Omnes, BNP Paribas Développement and Sham Innovation Santé invest an additional €5.2M on top of the €7.3M first closing announced in October 2017


Antabio SAS, a biopharmaceutical company developing novel antibacterial treatments in areas of highest unmet needs, announced today it has extended its Series A financing round with an additional €5.2 million subscribed by investment funds Omnes, BNP Paribas Développement, and Sham Innovation Santé (Turenne Capital). Existing shareholder Galia Gestion also participated in this extension. In October 2017, Antabio announced a first closing of its Series A financing round for €7.3 million subscribed by investment funds iXO Private Equity, IRDI SORIDEC Gestion, Galia Gestion and Antabio’s historical investor and former President of OM Pharma Christophe Ricard. The second closing brings the total raised in Series A to €12.5 million.

The new funding will be used to accelerate the development of Antabio’s novel inhibitor of bacterial metallo ßlactamases (“MBLs”) which will be combined with a carbapenem to fill an important gap in the treatment of drugresistant infections. Superbugs carrying MBLs (such as NDM-1) are spreading worldwide and cause lifethreatening drug-resistant infections that are deemed a critical medical priority by the WHO. There are currently no marketed inhibitors of MBLs.

The €12.5 million series A financing complements the CARB-X grant of up to $8.9 million awarded to Antabio in July 2017 to support the company’s Pseudomonas Elastase Inhibitor program (PEI) for the treatment of chronic Pseudomonas infections in Cystic Fibrosis patients.

“We are thrilled to welcome Omnes, BNP Paribas Développement, and Sham Innovation Santé to Antabio,” said Marc Lemonnier, CEO of Antabio. “We have built a strong international team of experts to combat the most urgent unmet medical needs in the antibacterial space. This extension to our series A, coupled with the substantial non-dilutive funding received from CARB-X, provides solid financial means for Antabio to take our innovative program into the clinic and move closer to this goal”.

Antibiotic resistance is a growing global health problem recognized as n°1 priority by the WHO. Today, 5 to 10% of hospital patients in the USA and Europe develop a hospital-acquired (nosocomial) infection with over 100,000 deaths due to drug-resistant bacterial infections per year and annual costs to public health exceeding €30 billion. On the horizon, alarming reports claim that by 2050 antimicrobial resistance will kill more people than cancer with an estimated 10 million people dying from resistant infections each year.

«Antibiotic resistance is one of the great challenges of our time. At Omnes, we were impressed by the innovative approach taken by the company to fight drug-resistant infections and we are delighted to support their strong international team to accelerate the development of their programs to the clinic» said Claire Poulard, Associate at Omnes.


About Omnes

Omnes is a leading Paris-based European investor in private equity and infrastructure. With €3.6 billion of assets under management, Omnes provides SMEs with the capital needed to finance growth. The firm has dedicated investment teams across three key areas: Venture Capital, Buyout & Growth Capital and Infrastructure. With more than 30 trade sales and nearly 15 IPOs in 19 years (including Novaled, Biovex, arGEN-X and Direct Energie), Omnes’ venture team is a leading French player in financing innovative SMEs with dual expertise in the deep-tech and healthcare sectors. Omnes is owned by its employees. Omnes is committed to ESG issues and has set up the Omnes Foundation in aid of children’s charities. It is also a signatory to the United Nations Principles for Responsible Investment (PRI).

More information on www.omnescapital.com

Press contacts :
Omnes Capital : Gaëlle de Montoussé, gaelle.demontousse@omnescapital.com – +33 1 80 48 79 16
Brackendale Consulting: Fay Margo, fay@brackendaleconsulting.com - +44 7962115825


About BNP Paribas Développement

BNP Paribas Développement, a BNP Paribas Group subsidiary founded in 1988, invests its own capital directly in promising small and medium-sized enterprises and mid-cap companies. As a minority shareholder in these target companies, BNP Paribas Développement seeks to promote their growth and ensure their longer-term prosperity by facilitating ownership transfer. In addition to providing financial resources so as to ensure the stability of any company in which BNP Paribas Développement invests, we also see our mission in helping the company management team to achieve its medium-term strategic plans. As a minority shareholder, our approach is to assist our partner with an appropriate level of governance, based on our experience of managing a portfolio of some 300 company shareholdings and backed by the strength of a world-class financial group, but without interfering in the day-to-day running of the partner company. Our policy of investing our own capital allows us to provide our partner companies with long-term backing suited to the nature of the particular business and its goals, and also enables us to act as an intermediary in such deals as capital re-organisations and external growth operations. In 2016, BNP Paribas Développement set up the WAI Venture Fund, which specialises in investing in Innovation-oriented companies, from the provision of seed capital through all subsequent funding rounds, with the aim of supporting the growth of high-potential startups.

Press contact: Olivier Durbize, olivier.durbize@bnpparibas.com - +33 1 40 14 66 28.
More information on www.bnpparibasdeveloppement.com


About Sham Innovation Santé

Launched in July 2014, Sham Innovation Santé is an evergreen Venture Capital Fund controlled and owned by Sham, a French mutual insurance company specializing in insurance and risk management for professionals in the health, social and socialmedical sectors and a French leader in civil liability (11,000 members in Europe – France, Italy, Spain, Germany –, € 2 billion in assets under management, 952 employees, revenues of € 438.2 million in 2018) Advised and managed by Turenne Capital, Sham Innovation Santé invests into biotech and medtech companies that are developing breakthrough technologies in the medical and biotechnology fields. The portfolio – 12 companies – is being gradually built up by new investments in the healthcare and life sciences field, with a target of € 50 million.

Press contact: Josépha Montana, jmontana@turennecapital.com - +33 6 01 21 21 49.
More information on www.sham.fr | www.turennecapital.com


About ANTABIO

Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need. Two of Antabio’s programs have received Wellcome Trust Seeding Drug Discovery Awards to date: [i] a novel, safe and efficacious inhibitor of bacterial metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections and [ii] a first-in-class inhibitor of Pseudomonas virulence to be co-administered with standard-of-care antibiotics for the long-term management of chronic respiratory infections. This second program has recently received up to $8.9 million funding from the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). The company’s lead product is expected to enter the clinic in 2019 with anticipated fast track approval. Antabio has built a best in class, international team of experts in the field to progress its pipeline. The Company is in the process of acquiring additional assets focused on Gram-negative antibiotic resistant therapies.

Press contact: Carine Bonnet-Danaire, press@antabio.com - +33 5 31 47 18 57.
More information on www.antabio.com and follow us on Twitter @antabio


ANTABIO • Biostep • 436 rue Pierre et Marie Curie • 31670 Labège- FRANCE www.antabio.com

   
Record changed: 2018-07-18

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Antabio S.A.S.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px




» top